Hepatocellular Carcinoma Clinical Trial
Official title:
Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients: Safety & Efficacy Registry in Taiwan (SUPER- Taiwan)
The purpose of this multicenter registry is to gather the safety, efficacy and survival data in intermediate and advanced HCC patients treated drug-eluting microsphere in Taiwan in order to provide clinical evidence in HCC management to physicians in the region, and to support the application of deTACE in treating advanced HCC patients.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | September 30, 2019 |
Est. primary completion date | September 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria:Patients must meet all of the following inclusion criteria in order to
be entered into the study: - Age 20 or older. - Patient has signed informed consent. - Patient must have a diagnosis of hepatocellular cancer confirmed by AASLD and at least one of the following method: - Magnetic resonance imaging (MRI) with early enhancement and delayed enhancement washout of at least one solid liver lesion > 1 cm. - Contrast enhanced computed tomography (CT) with early enhancement and delayed enhancement washout of at least one solid liver lesion > 1 cm. - Histological confirmation is required for lesions with inconclusive features. - Patient must not be suitable for treatment by resection or percutaneous ablation at time of study entry. - Patients not suitable for ablation due to lesion location may be enrolled. - Patients with HCC recurrence but not suitable for resection or ablation maybe enrolled. - Patient MUST be with either BCLC stage B OR C, and meet the following criteria: - Stage Child-Pugh A or B AND - Performance status ECOG = 1 WITH Vascular Invasion or WITHOUT Vascular invasion. - Patient has a life expectancy of at least 6 months. Exclusion Criteria:If patients meet any of the following criteria they may not be entered into the study: - Current or previous treatment with chemo- or radiation therapy or sorafenib or drug-eluting chemoembolization (deTACE). - Patients with concurrent cancer except non-melanomatous skin cancer. - Female patients who are pregnant, breastfeeding, or premenopausal and not using an effective method of contraceptive. - Performance status ECOG > 1. - Child-Pugh Class C. - Occlusive tumor thrombus to the main portal trunk. - Active gastrointestinal bleeding. - Evidence of uncorrectable bleeding diathesis. - Extra-Hepatic spread of the HCC. - Encephalopathy not adequately controlled medically. - Presence of ascites not controlled medically. - Any contraindication for MRI/ CT (eg. metallic implants). - Allergy to contrast media that cannot be managed with prophylaxis. - Any contraindication to arteriography. - Any contraindication for doxorubicin administration. - Any contraindication for hepatic embolization. Porto-systemic shunt, or an arteriovenous shunt that cannot be adequately closed prior to chemoembolization. Hepatofugal blood flow. Serum creatinine > 2mg/dL. Other condition deemed exclusionary by physician. Uncorrectable impaired clotting. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Taipei Veterans General Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
Taipei Veterans General Hospital, Taiwan | Chang Gung Memorial Hospital, China Medical University Hospital, National Taiwan University Hospital, Tri-Service General Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Exploratory Objectives, Time-To-Progression (TTP) | To define all participants from the day of the first HepaSphere Treatment until tumor progression or death is first reported, whichever comes first. | 1 year | |
Other | Exploratory Objectives, Downstaging | Tumor staging will be accessed according to BCLC staging system and Milan criteria, and will be reviewed at follow-up until end of study or death. | 1 year | |
Primary | Overall survival | To define all participants from the day of the first HepaSphere Treatment until end of study or death is reported, whichever comes first. | 1 year | |
Secondary | Tumor Response | Tumor response will be assessed using modified Response Evaluation Criteria In Solid Tumors (mRECIST) criteria to evaluate tumor necrosis under CT/ MRI and will be presented as %. | 1 year | |
Secondary | Adverse Event (AE) | Adverse event will be accessed according to CTCAE 4.0 after treatments until end of study or death. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |